| Aging of blood can be tracked by DNA methylation changes at just three CpG sites CI Weidner, Q Lin, CM Koch, L Eisele, F Beier, P Ziegler, DO Bauerschlag, ... Genome biology 15, 1-12, 2014 | 912 | 2014 |
| Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood N Rufer, TH Brümmendorf, S Kolvraa, C Bischoff, K Christensen, ... The Journal of experimental medicine 190 (2), 157, 1999 | 805 | 1999 |
| Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial JE Cortes, DW Kim, HM Kantarjian, TH Brümmendorf, I Dyagil, ... Journal of Clinical Oncology 30 (28), 3486-3492, 2012 | 574 | 2012 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 561 | 2018 |
| Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib JE Cortes, HM Kantarjian, TH Brümmendorf, DW Kim, AG Turkina, ... Blood, The Journal of the American Society of Hematology 118 (17), 4567-4576, 2011 | 547 | 2011 |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ... Journal of Clinical Oncology 36 (3), 231-237, 2018 | 508 | 2018 |
| Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure HJ Khoury, JE Cortes, HM Kantarjian, C Gambacorti-Passerini, ... Blood, The Journal of the American Society of Hematology 119 (15), 3403-3412, 2012 | 421 | 2012 |
| Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants R Hehlmann, M Lauseker, S Saußele, M Pfirrmann, S Krause, HJ Kolb, ... Leukemia 31 (11), 2398-2406, 2017 | 334 | 2017 |
| HER-2 amplification is highly homogenous in gastric cancer AH Marx, L Tharun, J Muth, AM Dancau, R Simon, E Yekebas, JT Kaifi, ... Human pathology 40 (6), 769-777, 2009 | 310 | 2009 |
| Telomere length in leukocyte subpopulations of patients with aplastic anemia TH Brümmendorf, JP Maciejewski, J Mak, NS Young, PM Lansdorp Blood, The Journal of the American Society of Hematology 97 (4), 895-900, 2001 | 290 | 2001 |
| Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase J Cortes, DW Kim, E Raffoux, G Martinelli, E Ritchie, L Roy, S Coutre, ... Leukemia 22 (12), 2176-2183, 2008 | 258 | 2008 |
| Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry TH Brümmendorf, TL Holyoake, N Rufer, MJ Barnett, M Schulzer, ... Blood, The Journal of the American Society of Hematology 95 (6), 1883-1890, 2000 | 252 | 2000 |
| Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study NP Shah, F Guilhot, JE Cortes, CA Schiffer, P Le Coutre, TH Brümmendorf, ... Blood, The Journal of the American Society of Hematology 123 (15), 2317-2324, 2014 | 242 | 2014 |
| Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 RK Schneider, M Schenone, MV Ferreira, R Kramann, CE Joyce, ... Nature medicine 22 (3), 288-297, 2016 | 240 | 2016 |
| Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial TH Brümmendorf, JE Cortes, CA de Souza, F Guilhot, L Duvillié, D Pavlov, ... British journal of haematology 168 (1), 69-81, 2015 | 226 | 2015 |
| Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations … A Gontarewicz, S Balabanov, G Keller, R Colombo, A Graziano, E Pesenti, ... Blood, The Journal of the American Society of Hematology 111 (8), 4355-4364, 2008 | 221 | 2008 |
| Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells S Appel, AM Boehmler, F Grünebach, MR Müller, A Rupf, MM Weck, ... Blood 103 (2), 538-544, 2004 | 213 | 2004 |
| Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry A Kaifie, M Kirschner, D Wolf, C Maintz, M Hänel, N Gattermann, ... Journal of hematology & oncology 9, 1-11, 2016 | 203 | 2016 |
| JAK inhibition impairs NK cell function in myeloproliferative neoplasms K Schönberg, J Rudolph, M Vonnahme, S Parampalli Yajnanarayana, ... Cancer research 75 (11), 2187-2199, 2015 | 190 | 2015 |
| Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer S Minner, B Jessen, L Stiedenroth, E Burandt, J Köllermann, M Mirlacher, ... Clinical Cancer Research 16 (5), 1553-1560, 2010 | 179 | 2010 |
S Koschmieder在 ukaachen.de 的电子邮件经过验证
